Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 450 of 2873 entries
View as:

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00553059 Org: User:
Start: 05/31/08 End: 08/31/14 Due: 08/31/15

Intravesical Cidofovir for Hemorrhagic Cystitis

Phase: N/A Priority: Normal
NCT ID: NCT01816646 Org: User:
Start: 09/30/13 End: 12/31/16 Due: 12/31/17

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00688168 Org: User:
Start: 05/09/08 End: 01/08/19 Due: 01/08/20

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02392039 Org: User:
Start: 12/14/15 End: 04/04/18 Due: 04/04/19

Study of Ixazomib and Erlotinib in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02942095 Org: User:
Start: 03/06/17 End: 12/07/22 Due: 12/07/23

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00968253 Org: User:
Start: 11/30/09 End: 12/31/15 Due: 12/31/16

Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00038701 Org: User:
Start: 08/31/99 End: 05/11/04 Due: 05/11/05

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

Phase: N/A Priority: Normal
NCT ID: NCT03862079 Org: User:
Start: 06/01/20 End: 12/31/21 Due: 12/31/22

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03395847 Org: User:
Start: 02/09/18 End: 01/27/23 Due: 01/27/24

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Phase: N/A Priority: Normal
NCT ID: NCT01712308 Org: User:
Start: 02/21/13 End: 05/24/22 Due: 05/24/23

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05947838 Org: User:
Start: 12/04/23 End: 04/30/26 Due: 04/30/27

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Phase: N/A Priority: Normal
NCT ID: NCT06263491 Org: User:
Start: 05/29/24 End: 03/01/27 Due: 03/01/28

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Phase: N/A Priority: Normal
NCT ID: NCT05667532 Org: User:
Start: 12/05/22 End: 12/31/27 Due: 12/31/28

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05115630 Org: User:
Start: 04/08/22 End: 05/15/25 Due: 05/15/26

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05091372 Org: User:
Start: 12/01/22 End: 12/31/27 Due: 12/31/28

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase: N/A Priority: Normal
NCT ID: NCT06817720 Org: User:
Start: 07/30/25 End: 03/07/27 Due: 03/07/28

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03862157 Org: User:
Start: 02/27/19 End: 01/31/27 Due: 01/31/28

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Phase: N/A Priority: Normal
NCT ID: NCT06660420 Org: User:
Start: 02/25/25 End: 12/31/31 Due: 12/31/32

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06522386 Org: User:
Start: 01/30/25 End: 02/28/29 Due: 02/28/30

Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

Phase: N/A Priority: Normal
NCT ID: NCT06329531 Org: User:
Start: 07/12/24 End: 12/01/27 Due: 12/01/28

Ovarian Cancer Patient Questionnaire on Genetic Testing

Phase: N/A Priority: Normal
NCT ID: NCT00486707 Org: User:
Start: 06/30/07 End: 10/31/08 Due: 10/31/09

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01880567 Org: User:
Start: 07/15/13 End: 07/31/26 Due: 07/31/27

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT04634617 Org: User:
Start: 01/09/20 End: 04/11/27 Due: 04/11/28

Smoking Cessation Treatment for Head & Neck Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01098955 Org: User:
Start: 03/24/10 End: 09/30/25 Due: 09/30/26

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04239157 Org: User:
Start: 08/25/20 End: 12/31/26 Due: 12/31/27